Precipio, Inc.

PRPO

HealthcareMedical - Diagnostics & ResearchNASDAQ

$30.40

Market Cap: $54.22M

Precipio, Inc. (PRPO) Valuation Summary

Updated May 11, 2026 20:42

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$5.18 – $318.94	$93.29	+206.9%
Revenue DCF 10Y	$34.35 – $588.21	$192.32	+532.6%
▸ Trading Multiples
EV/Revenue	$30.52 – $623.07	$26.46	-13.0%

Valuation History

DCF Analysis

Precipio, Inc. (PRPO) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$192.32

Market Price

$30.40

Upside / Downside

+532.6%

Verdict

Undervalued

Using a Revenue DCF model with operating margin convergence from -5.0% to a target of 13.2% over 5 years, discounted at a WACC of 8.3%, Precipio, Inc. (PRPO) has an intrinsic value of $192.32 per share (range: $34.35 – $588.21).

Key Assumptions

Current Operating Margin

-5.0%

Target Operating Margin

13.2%

WACC

8.3%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.9%

Target CapEx/Rev

17.5%

D&A/Revenue

11.7%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	80	233.7%	-1.4%	-1	-1	9	(3)	-0	5	5
2027	103	28.4%	2.3%	2	2	12	(6)	0	7	7
2028	132	28.4%	5.9%	8	6	15	(10)	1	11	9
2029	170	28.4%	9.6%	16	13	20	(15)	1	17	13
2030	218	28.4%	13.2%	29	23	25	(22)	1	25	18
2031	271	24.2%	13.2%	36	28	32	(32)	1	27	18
2032	325	19.9%	13.2%	43	34	38	(43)	1	28	17
2033	376	15.7%	13.2%	50	39	44	(55)	1	27	15
2034	419	11.5%	13.2%	55	44	49	(67)	1	24	12
2035	449	7.2%	13.2%	59	47	52	(79)	1	20	9

Enterprise Value Bridge

Sum of PV(FCFF)122

Terminal Value (Gordon Growth at 3.0%)391

PV of Terminal Value184

Enterprise Value306

(–) Net Debt-2

Equity Value309

(÷) Shares Outstanding2

Fair Value per Share$192.32

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
6.3%	$40	$166	$307	$447	$588
7.3%	$39	$132	$236	$340	$444
8.3%	$37	$111	$192	$274	$355
9.3%	$36	$96	$162	$228	$295
10.3%	$34	$85	$140	$196	$251

Current price: $30.40. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 2.0% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Precipio, Inc. (PRPO) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$93.29

Market Price

$30.40

Upside / Downside

+206.9%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-5.0%

Target Operating Margin

13.2%

WACC

8.3%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.9%

Target CapEx/Rev

17.5%

D&A/Revenue

11.7%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	80	233.7%	-1.4%	-1	-1	9	(5)	-0	4	4
2027	103	28.4%	2.3%	2	2	12	(9)	0	4	4
2028	132	28.4%	5.9%	8	6	15	(15)	1	6	5
2029	170	28.4%	9.6%	16	13	20	(25)	1	7	5
2030	218	28.4%	13.2%	29	23	25	(38)	1	9	6

Enterprise Value Bridge

Sum of PV(FCFF)24

Terminal Value (Gordon Growth at 3.0%)176

PV of Terminal Value123

Enterprise Value147

(–) Net Debt-2

Equity Value150

(÷) Shares Outstanding2

Fair Value per Share$93.29

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
6.3%	$5	$69	$152	$236	$319
7.3%	$5	$53	$116	$178	$241
8.3%	$5	$44	$93	$143	$193
9.3%	$5	$37	$78	$119	$160
10.3%	$5	$32	$67	$102	$136

Current price: $30.40. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 2.0% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$26.46

Market Price

$30.40

Upside / Downside

-13.0%

Verdict

Overvalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Precipio, Inc. (PRPO) has a fair value of $26.46 based on 4 comparable companies in the Medical - Diagnostics & Research industry.

EV/Revenue Valuation — Medical - Diagnostics & Research

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Precipio, Inc.PRPO	49	1.9x	5.2x
Milestone Scientific Inc.MLSS	37	4.1x	4.4x
Precision Optics Corporation, Inc.POCI	37	1.9x	—
Star Equity Holdings, Inc.STRR	34	0.3x	0.3x
Pluri Inc.PLUR	27	41.5x	0.9x
Industry Median		3.0x	0.9x
(*) Revenue		24	9
= Enterprise Value		72	8
(-) Net Debt		-2	-2
Equity Value		75	10
(/) Outstanding shares		2	2
Fair Price		$47	$6

Selected Fair Value (avg of trailing + forward)

$26.46

-13.0%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$5.18 – $318.94

$93.29

+206.9%

Revenue DCF 10Y

$34.35 – $588.21

$192.32

+532.6%

▸ Trading Multiples

EV/Revenue

$30.52 – $623.07

$26.46

-13.0%

DCF Analysis

Precipio, Inc. (PRPO) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$192.32

Market Price

$30.40

Upside / Downside

+532.6%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-5.0%

Target Operating Margin

13.2%

WACC

8.3%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.9%

Target CapEx/Rev

17.5%

D&A/Revenue

11.7%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	80	233.7%	-1.4%	-1	-1	9	(3)	-0	5	5
2027	103	28.4%	2.3%	2	2	12	(6)	0	7	7
2028	132	28.4%	5.9%	8	6	15	(10)	1	11	9
2029	170	28.4%	9.6%	16	13	20	(15)	1	17	13
2030	218	28.4%	13.2%	29	23	25	(22)	1	25	18
2031	271	24.2%	13.2%	36	28	32	(32)	1	27	18
2032	325	19.9%	13.2%	43	34	38	(43)	1	28	17
2033	376	15.7%	13.2%	50	39	44	(55)	1	27	15
2034	419	11.5%	13.2%	55	44	49	(67)	1	24	12
2035	449	7.2%	13.2%	59	47	52	(79)	1	20	9

Enterprise Value Bridge

Sum of PV(FCFF)122

Terminal Value (Gordon Growth at 3.0%)391

PV of Terminal Value184

Enterprise Value306

(–) Net Debt-2

Equity Value309

(÷) Shares Outstanding2

Fair Value per Share$192.32

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
6.3%	$40	$166	$307	$447	$588
7.3%	$39	$132	$236	$340	$444
8.3%	$37	$111	$192	$274	$355
9.3%	$36	$96	$162	$228	$295
10.3%	$34	$85	$140	$196	$251

Current price: $30.40. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 2.0% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$26.46

Market Price

$30.40

Upside / Downside

-13.0%

Verdict

Overvalued

EV/Revenue Valuation — Medical - Diagnostics & Research

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Precipio, Inc.PRPO	49	1.9x	5.2x
Milestone Scientific Inc.MLSS	37	4.1x	4.4x
Precision Optics Corporation, Inc.POCI	37	1.9x	—
Star Equity Holdings, Inc.STRR	34	0.3x	0.3x
Pluri Inc.PLUR	27	41.5x	0.9x
Industry Median		3.0x	0.9x
(*) Revenue		24	9
= Enterprise Value		72	8
(-) Net Debt		-2	-2
Equity Value		75	10
(/) Outstanding shares		2	2
Fair Price		$47	$6

Selected Fair Value (avg of trailing + forward)

$26.46

-13.0%